Home About Pipeline Team News Contact Us
Our Team

World-class expertise in epilepsy research and drug development

Our team of co-founders brings together discoverers of Keppra and ezogabine, leading clinical trialists, and translational researchers with over 150 years of combined experience.

Executive Team

7 co-founders shaping the future of epilepsy treatment

Our team combines deep expertise in basic science, drug development, and clinical trials to address critical unmet needs in epilepsy.

Pavel Klein

20+ years clinical epilepsy research. PI of largest phase 3 RCT of new anti-seizure medication. NIH and DOD-funded clinical post-traumatic epilepsy prevention trial leader.

Pavel Klein

Chief Executive Officer, Co-founder

Wolfgang Löscher

40+ years translational research. Discovered antiepileptic properties of levetiracetam (Keppra). One of the most cited epilepsy researchers globally. #1 ranked scholar in epilepsy.

Wolfgang Löscher

Chief Scientific Officer, Co-founder

Chris Rundfeldt

30+ years pharmaceutical industry experience. Discovered ezogabine/retigabine, first KCNQ/KV7 channel opener.

Chris Rundfeldt

Chief Operation Officer, Co-founder

Detlev Boison

25+ years translational epilepsy research. PI of antiepileptogenic drug discovery program with novel molecular targets.

Detlev Boison

Chief Development Officer, Co-founder

Alexander Rotenberg

20+ years of translational and clinical research experience. Professor at Harvard Medical School. Expert in transcranial magnetic stimulation biomarkers.

Alexander Rotenberg

Biomarker Development, Co-founder

Matthias Koepp

30+ years epilepsy therapeutic product development. Professor at UCL. Heads Epilepsy Clinical Trials Unit. Co-directed phase 3 post-stroke epilepsy prevention trial.

Matthias Koepp

VP Product Development, Co-founder

Eugen Trinka

30+ years epilepsy research and clinical trial experience. Chairman, Department of Neurology at Paracelsus Medical University. ILAE Vice President.

Eugen Trinka

Chief Medical Officer, Co-founder

Board of Directors

Strategic leadership and governance

Our board brings decades of pharmaceutical executive experience, from FDA drug approvals to clinical development leadership.

Pavel Klein

20+ years clinical epilepsy research. PI of largest phase 3 RCT of new anti-seizure medication. NIH and DOD-funded clinical post-traumatic epilepsy prevention trial leader.

Pavel Klein, MD

Chairman of the Board

Pierandrea Muglia

20+ years CNS drug development leadership. Founder of GRIN Therapeutics. Led Series A financing and Phase 3 advancement. Former CMO at multiple biotech companies. 100+ publications.

Pierandrea Muglia, MD

Board Member

Enrique Carrazana

Led VALTOCO® (diazepam nasal spray) FDA approval at Neurelis. Former CMO at Acorda Therapeutics, Global Head at Novartis. Harvard Medical School graduate. 140+ publications.

Enrique Carrazana, MD

Board Member

Wolfgang Löscher

40+ years translational research. Discovered antiepileptic properties of levetiracetam (Keppra). One of the most cited epilepsy researchers globally. #1 ranked scholar in epilepsy.

Wolfgang Löscher, PhD

Board Member

Advisory Board

Leading epilepsy ambassadors

Our company concept is supported by leading epilepsy ambassadors from NYU, UC Davis, UCB Biopharma, and other premier institutions.

Jacqueline A. French, M.D.

NYU Langone Health

Professor of Neurology and Director of clinical trials at NYU Langone's Comprehensive Epilepsy Center; Chief Scientific Officer, Epilepsy Foundation.

Michael A. Rogawski, M.D., PhD.

University of California, Davis

Professor of Neurology and Pharmacology, Director of Institute for Neurotherapeutics, University of California, Davis.

Elizabeth Garofalo, M.D.

EAG Pharma Consulting LLC

Principal for EAG Pharma Consulting LLC; former SVP, Novartis Pharmaceutical Corporation.

Annamaria Vezzani, Ph.D.

Mario Negri Institute, Milan

Professor of Neuroscience, Mario Negri Institute, Milan, Italy.

Henrik Klitgaard, Ph.D.

UCB Biopharma

Previous Vice President, Neurosciences Therapeutic Area, UCB Biopharma.

Ready to learn more?

Explore our innovative pipeline of epilepsy therapeutics or get in touch to discuss opportunities.

Explore Pipeline Contact Us